Form 4: Revvity SVP Granted Stock Options

Revvity's Senior Vice President, Chief Commercial Officer, Victor Miriame, was granted 32,382 non-qualified stock options with an exercise price of $90.465.

Summary

• Victor Miriame, Senior Vice President and Chief Commercial Officer of Revvity, Inc. (RVTY), was granted 32,382 non-qualified stock options.
• The options have an exercise price of $90.465 per share.
• These options are scheduled to fully vest on the third anniversary of the grant date, which is August 15, 2025.
• The options have a 7-year term, expiring on August 15, 2032.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, as it aligns management's incentives with long-term shareholder value creation. It reflects ongoing executive compensation practices.

Positives

• The grant of stock options aligns management's interests with shareholder value creation.
• The vesting schedule encourages long-term commitment from a key executive.

Risks

• The value of the stock options is contingent on Revvity's common stock price exceeding the exercise price of $90.465.
• The options will expire worthless if not exercised by August 15, 2032, or if the stock price remains below the exercise price.

Future Outlook

The vesting schedule and expiration date of the options indicate a future incentive for the executive, aligning their performance with future stock price appreciation.

Industry Context

Stock option grants are a standard component of executive compensation packages in the life sciences and diagnostics industry, aiming to incentivize long-term performance and align executive interests with shareholder returns.

Comparison to Industry Standards

• The grant of non-qualified stock options to a Senior Vice President is a common practice in publicly traded companies, including those in the life sciences and diagnostics sector like Revvity, Inc.
• The 7-year term and 3-year vesting schedule are typical for executive equity incentives, comparable to practices observed at companies such as Thermo Fisher Scientific (TMO) or Danaher Corporation (DHR) in their executive compensation structures.

Stakeholder Impact

• Shareholders: Potential for increased alignment between executive actions and shareholder interests.
• Employees: May signal stability in executive leadership.

Next Steps

• The executive will need to decide whether to exercise the options once they vest and if the stock price is favorable.

Key Dates

Keywords

Revvity, RVTY, Stock Options, Executive Compensation, Form 4, Insider Transaction, Equity Grant